A four-drug chemotherapy regimen provided longer overall survival than a two-drug combination in a phase III clinical trial for metastatic pancreatic ductal adenocarcinoma.
When Larry Einhorn was a young physician in the early 1970s, actinomycin-D was the standard drug used to treat testicular cancer. It was—and still is—the most common carcinoma in young men ages 15-35.
